An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Varlitinib in Healthy Male Subjects

Trial Profile

An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Varlitinib in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs Varlitinib (Primary)
  • Indications Biliary cancer; Breast cancer; Cholangiocarcinoma; Gastric cancer; Liver cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors ASLAN Pharmaceuticals
  • Most Recent Events

    • 08 Jan 2018 Status changed from recruiting to completed.
    • 18 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top